DDReg Knowledge Capsule

DDReg Pharma

🎧 DDReg Knowledge Capsule

Welcome to the DDReg Knowledge Capsule — your go-to podcast for concise, insightful conversations on the latest trends, innovations, and challenges in the life sciences industry. Brought to you by the experts at DDReg, this series distills complex regulatory affairs, pharmacovigilance, market access, and clinical development topics into easy-to-understand episodes.

Subscribe now and empower your pharma journey, one capsule at a time.

Play

Open in

31 episodes
Avg 20 min
English

Episodes 31

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Friday · 22 min
Navigate German Nutraceutical & Novel Food Compliance
When does a nutraceutical ingredient become a Novel Food regulatory concern? 🌿 Explore Germany’s nutraceutical market, EU Novel Food regulations, ingredient approval requirements, and key compliance challenges for businesses. 🎧 Tune in for insights into nutraceutical registration and regulatory compliance. #Nutraceuticals #NovelFood #Germany #FoodRegulations #RegulatoryAffairs For more info read our Blog: https://resource.ddregpharma.com/blogs/nutraceutical-registration-germany-novel-food/
Wednesday · 21 min
Japan & Malaysia: Faster Clinical Trial Approvals? 🌏
Can regulatory reliance accelerate clinical trial approvals in Japan and Malaysia? Discover how the new pilot could streamline regulatory reviews, reduce timelines, and shape the future of clinical research. 🎧 Tune in for insights on clinical trial regulations and global regulatory strategy. #ClinicalTrials #RegulatoryAffairs #Japan #Malaysia #ClinicalResearch For more info read our blog: https://resource.ddregpharma.com/blogs/clinical-trial-regulatory-reliance-japan-malaysia/
Monday · 21 min
Global-to-Local Pharmacovigilance: Bridging Safety Gaps
How can Marketing Authorization Holders (MAHs) prevent gaps between global and local safety teams? 🌍 Discover key strategies for stronger pharmacovigilance governance, effective communication, and regulatory compliance. 🎧 Tune in to explore smarter safety coordination and risk management. #Pharmacovigilance #DrugSafety #PatientSafety #RegulatoryAffairs To know more read our blog: https://resource.ddregpharma.com/blogs/global-to-local-pharmacovigilance-governance/
October 17 · 25 min
Realities of EAEU Pharmaceutical Registration
Welcome to DDReg Knowledge Capsule! In this episode, we unpack the complexities of pharmaceutical registration across the Eurasian Economic Union (EAEU)—covering Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan.While the EAEU Unified Procedure establishes a harmonised regional pathway for multi-state marketing authorisations, obtaining approval and maintaining post-market compliance still requires navigating critical member-state requirements.Key topics covered in this episode: Unified Procedure vs. National Pathways: How the reference-state and concerned-state evaluation system works, and when pursuing a national pathway (such as Russia’s Federal Law No. 61-FZ) may be strategically advantageous. EAEU CTD Dossier & Language Strategy: Navigating the 5-module CTD structure, managing local clinical data expectations, and addressing Russian, Armenian, and Kyrgyz translation requirements early. Post-Registration Fragmentations: Why a unified marketing authorization does not mean unified post-market compliance—exploring separate national pricing/reimbursement frameworks, distinct packaging/labelling guidelines, and non-centralised pharmacovigilance reporting systems (such as Roszdravnadzor in Russia). Post-2025 Compliance Realities: What marketing authorization holders need to know following the December 31, 2025 transition deadline for aligning legacy national registrations with EAEU rules For more check out blog - EAEU Pharmaceutical Registration: What’s Not Unified Procedure
October 16 · 17 min
Medical Device Registration in Kenya: Beyond Approval
Entering Kenya’s medical device market? 🌍 Discover the key regulatory requirements foreign manufacturers need to know beyond product registration, including local representation, importation, compliance, and post-market obligations. To know more about the Podcast Read our Blog: https://resource.ddregpharma.com/blogs/medical-device-registration-kenya-foreign-manufacturers/
October 13 · 24 min
Dietary Supplement Registration in Brazil vs. Mexico ANVISA and COFEPRIS Market Entry Pathways
"Welcome to the DDReg Knowledge Capsule" — This episode explores the contrasting regulatory pathways for entering the dietary supplement markets in Brazil and Mexico. It compares ANVISA's mandatory notification system in Brazil with COFEPRIS's compliance-focused framework in Mexico, detailing essential requirements for product classification, ingredient eligibility, local labeling rules, and import permit strategies needed for successful market entry.For more info Read our blog:https://resource.ddregpharma.com/blogs/dietary-supplement-registration-brazil-vs-mexico/
October 12 · 20 min
Strategic Regulatory Intelligence: Turning Regulatory Signals into Product Decisions
DDReg Knowledge Capsule, discover how pharmaceutical leaders move beyond passive regulatory monitoring to build a decision-oriented strategy that directly shapes product development. Learn how evaluating global health authority updates through product-specific context enables teams to assess impacts across clinical trials, CMC, dossier submissions, and post-approval lifecycles—ensuring every strategic shift is targeted, timely, and defensible For more Info Visit to Our Blog: https://resource.ddregpharma.com/blogs/regulatory-intelligence-strategy-product-decisions/
October 9 · 21 min
South Korea KDMF Requirements for Imported APIs
Welcome to the DDReg Knowledge Capsule" — This episode provides a practical overview of South Korea's Korea Drug Master File (KDMF) registration framework managed by the Ministry of Food and Drug Safety (MFDS) for imported active pharmaceutical ingredients (APIs). It explains how to determine registration scope, adapt global technical packages (such as US DMFs, ASMFs, or CEPs) to satisfy Korean requirements, choose between standalone and linked submission pathways, and maintain ongoing post-approval compliancevisit our blog - https://resource.ddregpharma.com/blogs/kdmf-registration-south-korea/
October 7 · 22 min
Regulatory Data Quality: The Hidden Risk Behind Submission & Compliance
Regulatory success depends on more than an accurate dossier. In today’s data-driven pharmaceutical environment, inconsistent product information across submissions, labeling, regulatory databases, and lifecycle activities can create submission delays, regulatory queries, rework, and compliance risks. In this episode, we explore why Regulatory Data Quality has become a critical priority for pharmaceutical companies, where data inconsistencies originate, and how poor data quality can impact regulatory submissions and post-approval lifecycle management. We also discuss the growing importance of Regulatory Information Management (RIM), IDMP, electronic Product Information (ePI), data governance, standardisation, validation controls, and continuous data monitoring. For visit our blog - Regulatory Data Quality: Submission & Compliance Risk
October 1 · 22 min
Pharmacovigilance Launch Readiness For Marketing Authorization Holders
Welcome back to the DDReg Knowledge Capsule! In this episode, we explore how Marketing Authorization Holders (MAHs) build and maintain compliant Pharmacovigilance (PV) governance structures as products transition to commercialization.We break down the core operational components of PV systems, including Qualified Person for Pharmacovigilance (QPPV) services, Individual Case Safety Report (ICSR) processing, literature monitoring, and signal managementWe also highlight how MAHs manage risk management strategies, aggregate safety reports, and audit and compliance controls to ensure ongoing patient safety and fulfill regulatory obligations post-approval.Finally, we outline how PV teams work alongside Regulatory Affairs to update regulatory authorities and maintain accurate product documentation. Visit our blog for more information - https://resource.ddregpharma.com/blogs/global-to-local-pharmacovigilance-governance/
September 29 · 21 min
The Strategic Role of Regulatory Affairs in Pharma Industry
In this edition of the DDReg Knowledge Capsule, we explore how Regulatory Affairs guides medicinal products from early research through market authorization and post-approval lifecycle management. Learn how RA teams establish global regulatory strategies, coordinate complex submissions, manage health authority interactions, and leverage digital tools to accelerate approval timelines while maintaining public health safety, quality, and efficacy Visit our blog - https://resource.ddregpharma.com/all-category/role-of-regulatory-affairs-in-the-pharmaceutical-industry/
September 24 · 18 min
Global Biosimilar Pathways 2026 : US, EU, UK & Asia
Welcome to the DDReg Knowledge Capsule! In this episode, we unpack the rapidly changing global regulatory landscape for biosimilar development across key target markets: the US (FDA), European Union (EMA), UK (MHRA), China (NMPA/CDE), and Japan (PMDA).We examine the pivotal 2026 transition away from routine comparative clinical efficacy trials toward tailored, risk-based evaluation frameworks grounded in high-resolution comparative analytical data, pharmacokinetic (PK) studies, and immunogenicity assessments.Key topics covered in this episode: Tailored Evidence Pathways: How regulators like the FDA, EMA, MHRA, and PMDA are evaluating biosimilarity without automatically requiring comparative efficacy studies. Reference Product Selection & Bridging: Navigating jurisdiction-specific reference rules and establishing scientific bridging between foreign comparators and local originators. Global Core Strategy: Designing one unified scientific dossier with planned regional adaptations to avoid duplicated clinical trials and submission delays Visit our blog - https://resource.ddregpharma.com/blogs/global-biosimilar-regulatory-strategy/
September 23 · 11 min
Registering Biosimilar Drugs with Health Canada
Welcome to DDReg Knowledge Capsule! In this episode, we explore Health Canada's regulatory framework for registering biosimilar biologic drugs. We break down the fundamental differences between biosimilars and generic small-molecule drugs, explain why biosimilars are authorized through the New Drug Submission (NDS) pathway, and discuss the pivotal role of the Canadian Reference Biologic Drug (CRBD). Listeners will also gain actionable insights into scientific reviews by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), indication extrapolation requirements, and post-market pharmacovigilance obligations Check out our blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-in-canada-guide/
September 18 · 21 min
Global Regulatory Operating Model For Pharma Leaders
This episode explores how pharmaceutical organisations can effectively structure regulatory roles across global, regional, and local markets. Based on the DDReg guide to global regulatory operating models, the discussion highlights the strategy of "controlled decentralization"—maintaining global consistency for core scientific positions while ensuring local authority ownership where jurisdiction-specific knowledge is critical.Key topics covered include: The five-layer operational structure: Defining decision rights across enterprise regulatory governance, product strategy, regional translation, local execution, and regulatory operations. Cross-functional coordination: Clarifying accountabilities between regulatory affairs, clinical development, CMC/quality, pharmacovigilance, and supply chain functions. Modern data standards & technology: How eCTD v4.0, ISO IDMP master data standards, Regulatory Information Management (RIM) systems, and AI in 2026 are reshaping regulatory workflows and data governance
September 11 · 22 min
Mastering Global CMC Variations & Life Cycle Management
Welcome to DDReg Knowledge Capsule! In this episode, we dive into the complex world of global post-approval change management in the pharmaceutical industry.When a drug product undergoes a single internal scientific or manufacturing modification—such as a site transfer, process modification, or analytical method update—it can trigger dozens of distinct regulatory submissions across international jurisdictions. This episode explores why global pharmaceutical companies must separate the globally controlled scientific change from market-specific regulatory pathways. For more, visit our blog: https://resource.ddregpharma.com/blogs/global-variation-management-post-approval-change/
September 4 · 22 min
Malaysia NPRA 2026: Fast Route for Biosimilar Registration
Welcome to the DDREG Knowledge Capsule. In this episode, we unpack the National Pharmaceutical Regulatory Agency's (NPRA) landmark 2026 reliance pilot pathway in Malaysia. We explore how eligible biosimilars with prior US FDA or EMA approval can now access an accelerated 60-working-day registration timeline.However, this rapid timeline is far from automatic. We break down the strict parameters sponsors must navigate to succeed, including the critical three-month post-approval submission window, rigorous dossier sameness requirements, and NPRA-specific local additions like ASEAN Zone IVb stability data. Tune in to discover how global biopharma teams can proactively adapt their launch strategies to successfully leverage this new pathway For more ready this blog - https://resource.ddregpharma.com/blogs/biosimilar-registration-malaysia-npra/
August 31 · 21 min
Mandatory EUDAMED Compliance for German Medical Devices 2026
Welcome to this episode of the DDReg Knowledge Capsule. In this session, we break down Germany's critical regulatory transition from the national DMIDS database to the EU-wide EUDAMED platform. We explore the operational modules that became mandatory on 28 May 2026—including Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance—and clarify the upcoming 28 November 2026 transition deadline for legacy and MDR/IVDR devices. Listeners will learn about the process for validating Single Registration Numbers (SRNs) in Germany, the special requirements for non-EU manufacturers working with authorised representatives, and how to avoid costly compliance errors like assuming automatic data migration from DMIDS. For more, visit our blogs: https://resource.ddregpharma.com/blogs/eudamed-mandatory-registration-germany-bfarm/
August 27 · 17 min
India's Pharma Shift from Generics to Innovation
India is evolving from "the pharmacy of the world" to a powerhouse of pharmaceutical innovation, focusing on biosimilars, complex generics, and advanced therapies. In this episode, we unpack how this transition is fundamentally reshaping global regulatory strategies, clinical trial expectations, and FDA compliance for companies targeting international marketsVisit our blog for more: https://resource.ddregpharma.com/blogs/india-pharmaceutical-industry-innovation/
August 21 · 17 min
Why Gene Therapy Manufacturing Fails FDA
Why do even the most revolutionary gene therapies with promising clinical results face critical roadblocks on their path to commercial approval? In this episode of the DDReg Knowledge Capsule, we delve deep into the core reasons behind Biologics License Application (BLA) delays, focusing on common Chemistry, Manufacturing, and Controls (CMC) pitfalls, weak analytical strategies, and limited comparability data.We unpack the regulatory expectations of the FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Therapeutic Products (OTP), highlighting why early regulatory alignment, rigorous product characterisation, and proven manufacturing consistency are absolutely vital for success. Whether you are navigating vector-related complexities, scale-up challenges, or preparing for critical pre-BLA meetings, this episode provides the strategic insights needed to ensure your manufacturing, clinical, and quality teams are fully aligned for FDA readinessRead this Blog: https://resource.ddregpharma.com/blogs/gene-therapy-bla-submission-regulatory-strategy/
August 16 · 20 min
Navigating the UAE's MOHAP to EDE Transition
Welcome to the DDReg Knowledge Capsule. In this episode, we unpack the historic shift in the UAE’s healthcare regulatory framework as the Emirates Drug Establishment (EDE) takes over medical device oversight from the Ministry of Health and Prevention (MOHAP). Established under Federal Decree-Law No. 38 of 2024, the EDE centralizes compliance across all seven emirates. We discuss critical updates for manufacturers and distributors, from key technical dossier requirements (such as CE Marks and FDA clearances) to the new 45-working-day completion timeline and the 5-year marketing authorization validity. Tune in to discover how to align your regulatory strategy and secure faster access to the UAE market. https://resource.ddregpharma.com/blogs/uae-mohap-to-ede-transition-medical-devices-regulations/

Showing 1–20 of 31 episodes